Wintac Limited was started in the year 1987 with the name of Recon Limited and as an offspring of Bangalore Pharmaceutical and Research Laboratories Pvt. Ltd which has been in existence since 1956. The company shot into prominence for launching quality products which were within the reach...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 6.74%-7.93%-32.35%-9.94%-17.62%-58.12%-46.93%-113.88%14.2%-1.82%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 26.724.320.930.529.518.132.844.471.985.1
Y-o-Y Gr. Rt.--9%-14%46%-3.3%-38.6%81.2%35.2%62.2%18.3%
Adjusted EPS (Rs.) 1.77-9.04-16.36-4.4-5.9-16.15-9.45-9.723.92-2.08
Y-o-Y Gr. Rt.--610.7%NANANANANANANA-153.1%
Book Value per Share (Rs.) 42.0132.5242.2935.3129.1714.085.66-4.21-4.37-8.15
Adjusted Net Profit 0.9-5.4-16.4-4.4-5.9-16.2-9.5-9.83.9-2.1
Net Op. Cash Flow (Rs. Cr.) 3.53.9-3-6.56-3.94.318.2-4.160.4
Debt to Cash Flow from Ops 5.865.03-1.27-0.150.06-2.51.850.37-16.270.47
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Wintac Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 13.8%23.6%37.4%18.3%
Adjusted EPS -201.8%NANA-153.1%
Book Value per Share -183.3-177.5-212.90
Share Price 30.1% 13% 13.3% 280%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) 3.98-24.37-49.71-11.05-18.3-74.66-95.73-1342.64-91.3233.31
Operating Profit Margin (%) 18.61-1.44-13.25-4.05-5.22-70.77-23.15-13.2512.285.65
Net Profit Margin (%) 3.17-22.43-78.54-14.47-20.07-89.44-28.88-21.985.46-2.46
Debt to Equity 0.880.90.090.030.010.691.39-1.59-15.17-3.48
Working Capital Days 292332297189191243174195168178
Cash Conversion Cycle 63683929358954453050
Entity Percentage Holding
Promoters 54.99%
Institutions 0.01%
Non-Institutions 45.00%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Wintac Ltd's performance infers:

Wintac Ltd earnings have grown by 0%, whereas share price has appreciated 13% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Wintac Ltd share prices over the last 10 years. Here is what we found out:

Wintac Ltd share price has appreciated 24.6% annually over the past ten years.

Wintac Limited was started in the year 1987 with the name of Recon Limited and as an offspring of Bangalore Pharmaceutical and Research Laboratories Pvt. Ltd which has been in existence since 1956. The company shot into prominence for launching quality products which were within the reach of common man. Over the years, Recon leveraged its expertise in launching products that encompassed a wide range of therapeutic specialties.

In 2001 -   Recon  was renamed as Wintac

Wintac Limited was started in the year 1987 with the name of Recon Limited and as an offspring of Bangalore Pharmaceutical and Research Laboratories Pvt. Ltd which has been in existence since 1956. The company shot into prominence for launching quality products which were within the reach of common man. Over the years, Recon leveraged its expertise in launching products that encompassed a wide range of therapeutic specialties.

In 2001 -   Recon  was renamed as Wintac Limited, coined from We INtend TAking  Care (WINTAC) its range of specialties includes Antifungal, Anticancer, Cardiovascular, Corticosterid , Antiemetic, Large and small volume injectable and Ophthalmic solutions.

Wintac Limited has now forayed into the field of critical care by manufacturing and marketing products targeted to the critically ill patients. It is a fully integrated pharmaceutical company that creates, develops, manufactures and distributes healthcare products that improve the quality of life. It currently, market specialty products under a strategic alliance between Tech I Ventures Inc., USA, Alza Corporation USA and other prospective business partners. It is thus committed to meet critical health needs by providing that winning edge in critical times. its success stems from its un-wavering commitment to technology.

The state-of-the-art manufacturing plant located at the outskirts of the city of Bangalore and has been awarded the ISO 9001 certification from DNV Germany. All the products manufactured here conform to stringent quality control, recommended and specified in the U. S, British and Indian pharmacopoeia. The facility which is on 16 acres of land has a total built-up area of over 85,000 sq. ft. and consists of a capsule unit and a sterile unit. The sterile unit is about 70,000 sq. ft. including exclusive suite for Ophthalmic preparation

Product range of the company includes:

  • Antifungal- Amphocil, which contains Amphotercin B Colloidal dispersion for injection, is a novel formulation of Amphotericin B for life threatening fungal infections.
  • Anticancer- Wintac Joins the country's crusade in fighting cancer by providing high quality products at affordable prices.
  • Cardiovascular- Dobucare, which contains Dobutamine, is extensively used for short-term inotropic support in acute cardiac decompensation due to organic heart disease.
  • Corticosteroid- Metypred containing Methylprednisolone sodium succinate injection is a versatile corticosteroid of diverse utility and value in various heart diseases.
  • Antiemetic- When Cytotoxic Chemotherapy and Radiotherapy induces nausea & Vomiting in cancer Patients , Emitron effectively controls nausea and vommiting ensuring patient compliance.
  • Ophthalmics- Wide range ophthalmic preparations are available in three piece ophthalmic containers manufactured from fully automated plant.

Awards/achievements

Wintac is approved by AFSSAPS (Agence Francaise de Securite Sanitaire des Produits de Sante).

ISO 9001 certification from DNV Germany.

Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback